Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,787.00+5.07%ETH$2,431.65+7.47%GOLD$4,134.30+1.51%OIL$87.17-1.08%
Smart Investors Daily
SID Premium
LG

NASDAQ · LGVN

Longeveron Inc. Common Stock

Healthcare · Biotechnology

$1.78

Up+$0.00 (+0.00%)

Updated Nov 5, 2026, 3:29 AM

SID Score

5.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
13.34M
P/E ratio
-0.54
Dividend yield
0.00%
52-week range
$0.49 – $8.70
Volume
61.45K
Avg. volume
453.73K

Price performance · LGVN

LGVN price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 4, 2026

LGVN closed at $1.78 after 21 trading sessions, down 27.05% for the selected period.

Last close
$1.78
Period change
-27.05%
Period low
$1.39
Period high
$2.48
Daily close
View OHLC price history
LGVN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 4, 2026$1.76$1.82$1.75$1.7861.45K
Nov 3, 2026$1.71$1.80$1.71$1.7838.18K
Nov 2, 2026$1.74$1.79$1.655$1.7163.49K
Oct 30, 2026$1.78$1.80$1.5811$1.6780.81K
Oct 29, 2026$1.75$1.83$1.7307$1.7564.78K
Oct 28, 2026$1.74$1.83$1.70$1.7884.88K
Oct 27, 2026$1.62$1.76$1.62$1.7390.74K
Oct 26, 2026$1.55$1.86$1.50$1.60591.18K
Oct 23, 2026$1.58$1.68$1.4764$1.6064.38K
Oct 22, 2026$1.41$1.64$1.41$1.5973.53K
Oct 21, 2026$1.49$1.53$1.42$1.4382.15K
Oct 20, 2026$1.40$1.52$1.36$1.5050.61K
Oct 19, 2026$1.40$1.5074$1.31$1.3956.35K
Oct 16, 2026$1.47$1.4906$1.36$1.3966.06K
Oct 15, 2026$1.68$1.7097$1.37$1.50150.41K
Oct 14, 2026$2.11$2.11$1.69$1.73158.74K
Oct 13, 2026$2.42$2.445$2.14$2.1560.61K
Oct 12, 2026$2.49$2.55$2.42$2.4534.9K
Oct 9, 2026$2.40$2.60$2.34$2.4858.46K
Oct 8, 2026$2.45$2.57$2.32$2.3777.3K
Oct 7, 2026$2.33$2.48$2.33$2.4458.12K

Latest LGVN news

The latest Smart Investors Daily articles mentioning LGVN.

Stock researchCompany · Overview

LGVN research

Overview

Company profile and research snapshot.

Company profile

Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$10.00
Implied upside
—
Analysts
—
LGVN recent ratings
DateFirmRatingTarget
May 11, 2026Maxim GroupHold—
May 4, 2026HC Wainwright & Co.Buy—
Aug 15, 2025Roth CapitalBuy—
Mar 21, 2025HC Wainwright & Co.Buy—
Mar 3, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 28, 2026

Longeveron Announces Engagement of Lucid Capital Markets

MIAMI, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (the “Company”) (NASDAQ: LGVN), today announced that the Company has retained Lucid Capital Markets, LLC as the Company’s financial advisor to explore potential strategic opportunities, including a potential business combination. About Longeveron Inc. Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company’s lead investigational product is laromestrocel (Lomecel-B®)

Yahoo · Oct 26, 2026

Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Important Secondary Clinical Outcome Endpoint MACE Achieved Statistical SignificanceELPIS II 2 Data in HLHS Selected for Late-Breaking Science Program Podium Presentation in the American Heart Association’s (AHA) 2026 Scientific Sessions As previously reported, the ELPIS II trial did not meet the primary endpoint of increase in right ventricular ejection fraction (RVEF) at month 12 and the Company planned to continue analysis of additional dataAdditional analysis demonstrates an important pre-sp

Yahoo · Sep 30, 2026

Longeveron to Participate in Three Longevity/Aging Investment Conferences

New Data Analysis from Phase 2a Clinical Trial in Alzheimer’s Disease (AD) Indicating That Laromestrocel Treatment May Reduce Neuroinflammation in the Brain, A Core Driver of AD Pathogenesis, Published on medRxivMIAMI, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in three upcoming Longe

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By